Ensysce Biosciences (ENSC) Tax Provisions (2018 - 2021)
Ensysce Biosciences (ENSC) posted quarterly Tax Provisions of -$61278.0 for Q1 2021, down 182.11% year-over-year from $74625.0 in Q1 2020, and down 182.11% quarter-over-quarter from $74625.0 in Q1 2020.
Ensysce Biosciences (ENSC) Tax Provisions (2018 - 2021) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Tax Provisions for 4 consecutive years, with -$61278.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Tax Provisions fell 182.11% year-over-year to -$61278.0; the TTM figure through Mar 2021 stood at $126977.0 (down 69.44% YoY), while the FY2020 annual figure was $244493.0, down 55.96% from the prior year.
- Tax Provisions retreated to -$61278.0 in Q1 2021 per ENSC's latest filing, from $74625.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $227214.0 in Q2 2019 and bottomed at -$61278.0 in Q1 2021.
- Historically, Tax Provisions has averaged $112069.9 across 4 years, with a median of $121450.5 in 2018.
- Annual changes were most pronounced in 2019 — Tax Provisions soared 89.5% — and 2021, when it sank 182.11%.
- Ensysce Biosciences' Tax Provisions stood at $179126.0 in 2018, then sank by 44.56% to $99312.0 in 2019, then decreased by 24.86% to $74625.0 in 2020, then tumbled by 182.11% to -$61278.0 in 2021.
- Business Quant data shows ENSC's Tax Provisions at -$61278.0 in Q1 2021, $74625.0 in Q1 2020, and $99312.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -61,278.00 |
| Mar 31, 2020 | 74,625.00 |
| Dec 31, 2019 | 99,312.00 |
| Sep 30, 2019 | 14,318.00 |
| Jun 30, 2019 | 227,214.00 |
| Mar 31, 2019 | 214,356.00 |
| Dec 31, 2018 | 179,126.00 |
| Sep 30, 2018 | 130,125.00 |
| Jun 30, 2018 | 129,786.00 |
| Mar 31, 2018 | 113,115.00 |